Research and Markets: A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Marke

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/c38a9a/a_decision_support) has announced the addition of the "A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market" report to their offering.

This report comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 152 companies, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five sub-indications of lymphoma. BioSeeker has applied its unique drug assessment methodology to stratify the lymphoma pipeline and discern the level of competition in fine detail.

Major findings from this report:

  • The identified competitive landscape of lymphoma drugs is split between the 49% which have unique drug target strategies and the other part which have head-to-head target competing lymphoma drugs in 36 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the lymphoma drugs in general. Contributing to this fact is heavily utilized drug target strategies like: MS4A1, TOP2A, ALK and CD19.
  • Eight out of ten drug target strategies in Phase III development are new to lymphoma drugs and at the same time the greatest numbers of new target strategies are found in Phase I (33%) and Phase II development (27%).
  • Small molecules, antibodies and proteins are the dominating compound strategies of lymphoma drugs, which represent 90% of the entire pipeline. Cell- and gene therapy based lymphoma drugs have the lowest representation in the defined target strategy portfolio compared to that of other compound strategies of lymphoma drugs.
  • The highest number of described drug target strategies of lymphoma drugs belongs to Bristol-Myers Squibb (9), Hoffmann-La Roche (8), GlaxoSmithKline (8) and Pfizer (8).

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty.

The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any lymphoma drug to ensure that the optimal market conditions exist by the time the product is commercialized.

For more information visit http://www.researchandmarkets.com/research/c38a9a/a_decision_support



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.